^
Phase 2/3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/15/2021
Initiation :
08/06/2020
Primary completion :
08/23/2024
Completion :
08/23/2024
PD-L1 • IDH1 • MGMT
|
IDH1 R132H • MGMT promoter methylation
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase 2
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
10/14/2021
Initiation :
02/12/2019
Primary completion :
12/22/2023
Completion :
12/22/2023
HER-2 • PD-L1 • ER • PGR
|
Keytruda (pembrolizumab) • lenvatinib
Phase 1
Taiho Oncology, Inc.
Recruiting
Last update posted :
10/14/2021
Initiation :
09/16/2021
Primary completion :
05/01/2025
Completion :
06/01/2025
EGFR • HER-2
|
HER-2 positive
|
TAS2940
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/14/2021
Initiation :
03/27/2019
Primary completion :
02/28/2025
Completion :
02/27/2026
TMB • IDH1 • IDH2
|
IDH2 mutation
|
Opdivo (nivolumab)
Phase 1
Nader Sanai
Not yet recruiting
Last update posted :
10/13/2021
Initiation :
10/01/2021
Primary completion :
10/01/2022
Completion :
10/01/2024
IDH1 • IDH2 • ATRX • PARP1
|
IDH2 mutation • ATRX mutation
|
Zejula (niraparib)
Phase 3
Denovo Biopharma LLC
Recruiting
Last update posted :
10/13/2021
Initiation :
12/16/2020
Primary completion :
06/01/2025
Completion :
06/01/2025
MGMT
|
MGMT promoter methylation
|
temozolomide • Kinenza (enzastaurin)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/12/2021
Initiation :
10/31/2018
Primary completion :
10/29/2024
Completion :
10/29/2024
BRAF
|
BRAF V600E
|
temozolomide • veliparib (ABT-888)
Phase 1
Dana-Farber Cancer Institute
Completed
Last update posted :
10/12/2021
Initiation :
09/21/2016
Primary completion :
10/01/2021
Completion :
10/01/2021
ALB
|
Keytruda (pembrolizumab)
Phase 1/2
VBI Vaccines Inc.
Active, not recruiting
Last update posted :
10/12/2021
Initiation :
12/06/2017
Primary completion :
03/01/2022
Completion :
03/01/2022
MGMT • IFNG • CSF2
|
VBI-1901
Phase 1
Nader Sanai
Recruiting
Last update posted :
10/11/2021
Initiation :
10/01/2016
Primary completion :
06/01/2022
Completion :
11/01/2022
CDKN2A • CCND1 • CDK4 • CDKN2B
|
CDKN2A deletion • CCND1 amplification • CDK4 amplification
|
Kisqali (ribociclib)
Phase 1/2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
10/08/2021
Initiation :
06/01/2016
Primary completion :
06/01/2022
Completion :
06/01/2022
TNFA • IL2 • GZMB
|
temozolomide
Phase 1
Sidney Kimmel Comprehensive Cancer Center at Jo...
Recruiting
Last update posted :
10/07/2021
Initiation :
01/02/2020
Primary completion :
12/01/2022
Completion :
12/01/2023
AXL
|
AXL expression
|
bemcentinib (BGB324)
Phase 2
Andrew Sloan, MD
Not yet recruiting
Last update posted :
10/07/2021
Initiation :
10/15/2021
Primary completion :
06/01/2023
Completion :
12/01/2023
IDH1 • MGMT • CD34
|
IDH2 mutation
|
temozolomide • carmustine • Neupogen (filgrastim)
Phase 1
Boehringer Ingelheim
Recruiting
Last update posted :
10/05/2021
Initiation :
05/03/2018
Primary completion :
03/01/2023
Completion :
07/04/2023
PD-L1
|
PD-L1 expression
|
BI 836880 • ezabenlimab (BI 754091)
Phase 1
University of California, San Francisco
Recruiting
Last update posted :
10/05/2021
Initiation :
04/03/2019
Primary completion :
06/30/2022
Completion :
07/30/2027
IDH1 • IDH2
|
IDH2 mutation
|
temozolomide • Partruvix (pamiparib)
Phase 1
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
10/04/2021
Initiation :
07/11/2018
Primary completion :
11/18/2024
Completion :
11/18/2024
HER-2
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • lenvatinib • pemetrexed • MK-4830
Phase 1/2
Inovio Pharmaceuticals
Active, not recruiting
Last update posted :
10/04/2021
Initiation :
05/31/2018
Primary completion :
12/30/2021
Completion :
12/30/2021
IFNG
|
temozolomide • Libtayo (cemiplimab) • INO-5401 • rocakinogene sifuplasmid (INO-9012)
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/04/2021
Initiation :
02/26/2018
Primary completion :
12/31/2021
Completion :
12/31/2021
TP53 • MGMT • GDF15 • CDKN1A
|
GDF15 elevation
|
navtemadlin (KRT-232)
Phase 2
CNS Pharmaceuticals, Inc.
Recruiting
Last update posted :
10/04/2021
Initiation :
05/18/2021
Primary completion :
10/01/2024
Completion :
02/01/2025
MGMT
|
lomustine • berubicin (RTA 744)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
10/01/2021
Initiation :
09/21/2017
Primary completion :
01/09/2023
Completion :
01/09/2025
PD-L1 • MGMT
|
Keytruda (pembrolizumab) • temozolomide • Oncophage (Heat Shock Protein Peptide Complex-96)
Phase 1
Chembrain LTD
Active, not recruiting
Last update posted :
10/01/2021
Initiation :
05/15/2020
Primary completion :
10/01/2023
Completion :
10/01/2023
EGFR
|
EGFR expression
Phase 1/2
Novartis Pharmaceuticals
Active, not recruiting
Last update posted :
09/30/2021
Initiation :
10/21/2016
Primary completion :
03/17/2022
Completion :
03/17/2022
CD163
|
spartalizumab (PDR001) • BLZ-945
Phase N/A
NaviFUS Corporation
Recruiting
Last update posted :
09/29/2021
Initiation :
09/23/2021
Primary completion :
10/07/2022
Completion :
01/06/2023
FUS
Phase 1
Sidney Kimmel Comprehensive Cancer Center at Jo...
Recruiting
Last update posted :
09/28/2021
Initiation :
02/18/2020
Primary completion :
09/01/2022
Completion :
09/01/2024
MGMT
|
spartalizumab (PDR001) • sabatolimab (MBG453)
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
09/28/2021
Initiation :
12/14/2016
Primary completion :
08/26/2020
Completion :
08/26/2020
TP53 • ATRX
|
temozolomide • zotiraciclib (TG02)
Phase 1b
Celgene
Recruiting
Last update posted :
09/27/2021
Initiation :
07/10/2020
Primary completion :
04/12/2023
Completion :
11/20/2024
ALB
|
temozolomide • trotabresib (CC-90010)
Phase 2
Gary Archer Ph.D.
Suspended
Last update posted :
09/27/2021
Initiation :
09/30/2019
Primary completion :
12/01/2023
Completion :
12/01/2023
MGMT • IFNG • TNFA • IL2 • CSF2 • CD4 • LAMP1
|
temozolomide • Leukine (sargramostim)
Phase 2
Wake Forest University Health Sciences
Recruiting
Last update posted :
09/24/2021
Initiation :
03/25/2019
Primary completion :
09/30/2022
Completion :
09/30/2022
APOE
|
ramipril
Phase 2/3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
09/24/2021
Initiation :
11/15/2010
Primary completion :
09/27/2016
ALB
|
Avastin (bevacizumab) • temozolomide • Zolinza (vorinostat) • Mvasi (bevacizumab biosimilar) • Zirabev (bevacizumab biosimilar) • BP102 (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CT-P16 (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • HD204 (bevacizumab biosimilar) • HLX-04 (bevacizumab biosimilar) • MIL 60 (bevacizumab biosimilar)
Phase 1
Ziopharm
Completed
Last update posted :
09/22/2021
Initiation :
09/05/2018
Primary completion :
04/02/2019
Completion :
01/19/2021
CD8 • IFNG • CD4
|
Ad-RTS-hIL-12 • veledimex (INXN-1001)
Phase 1
Pediatric Brain Tumor Consortium
Recruiting
Last update posted :
09/22/2021
Initiation :
05/27/2020
Primary completion :
03/31/2022
Completion :
12/31/2023
CD4
|
aderbasib (INCB7839)
Phase 2
Kadmon Corporation, LLC
Completed
Last update posted :
09/22/2021
Initiation :
06/01/2016
Primary completion :
04/30/2020
Completion :
04/30/2020
EGFR
|
EGFR amplification
|
tesevatinib (KD019)
Phase 1
Pediatric Brain Tumor Consortium
Recruiting
Last update posted :
09/22/2021
Initiation :
02/02/2018
Primary completion :
03/31/2022
Completion :
09/30/2022
TMB • CD4
|
sotigalimab (APX005M)
Phase 1
European Organisation for Research and Treatmen...
Active, not recruiting
Last update posted :
09/21/2021
Initiation :
06/12/2018
Primary completion :
01/01/2022
Completion :
01/01/2022
IDH1 • IDH2 • MCL1 • CDK9
|
IDH1 R132H
|
temozolomide • zotiraciclib (TG02)
Phase 2
University of Aarhus
Withdrawn
Last update posted :
09/20/2021
Initiation :
01/01/2015
Primary completion :
01/01/2018
Completion :
05/31/2019
MGMT
|
temozolomide
Phase 2
OHSU Knight Cancer Institute
Recruiting
Last update posted :
09/17/2021
Initiation :
12/20/2017
Primary completion :
08/30/2023
Completion :
05/30/2024
PD-L1
|
Keytruda (pembrolizumab) • Feraheme (ferumoxytol injection)
Phase 2
PharmAbcine
Recruiting
Last update posted :
09/16/2021
Initiation :
11/13/2019
Primary completion :
12/30/2021
Completion :
06/30/2022
IDH1
|
IDH1 mutation
|
Avastin (bevacizumab) • olinvacimab (TTAC-0001)
Phase 1
Bicara Therapeutics
Recruiting
Last update posted :
09/15/2021
Initiation :
06/01/2020
Primary completion :
12/31/2022
Completion :
06/01/2023
EGFR • PD-L1 • KRAS
|
KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • KRAS G13 • KRAS G12 • EGFR negative
|
Keytruda (pembrolizumab) • BCA101
Phase 1
Milton S. Hershey Medical Center
Not yet recruiting
Last update posted :
09/14/2021
Initiation :
10/01/2021
Primary completion :
05/01/2023
Completion :
05/01/2023
VEGFA • HK2
|
VEGFA expression
|
Noxafil (posaconazole)
Phase 1
Milton S. Hershey Medical Center
Not yet recruiting
Last update posted :
09/14/2021
Initiation :
10/01/2021
Primary completion :
05/01/2023
Completion :
05/01/2023
VEGFA • HK1
|
VEGFA expression
|
ketoconazole
Phase 2
Cecilia Soderberg-Naucler
Recruiting
Last update posted :
09/13/2021
Initiation :
09/04/2019
Primary completion :
08/31/2024
Completion :
08/31/2024
MGMT
|
MGMT promoter methylation
|
temozolomide • Valcyte (valganciclovir)
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Recruiting
Last update posted :
09/10/2021
Initiation :
07/29/2019
Primary completion :
07/01/2025
Completion :
07/01/2027
BRAF
|
Braftovi (encorafenib) • Mektovi (binimetinib)
Phase 1
Sidney Kimmel Comprehensive Cancer Center at Jo...
Active, not recruiting
Last update posted :
09/10/2021
Initiation :
08/24/2016
Primary completion :
03/05/2021
Completion :
02/01/2022
MGMT
|
Opdivo (nivolumab) • relatlimab (BMS-986016) • urelumab (BMS-663513)
Phase 1/2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Recruiting
Last update posted :
09/10/2021
Initiation :
01/03/2020
Primary completion :
04/01/2022
Completion :
07/01/2023
IDH1 • IDH2
|
IDH2 R140 • IDH2 R172
|
temozolomide • Partruvix (pamiparib)
Phase N/A
Sidney Kimmel Comprehensive Cancer Center at Jo...
Not yet recruiting
Last update posted :
09/10/2021
Initiation :
12/01/2021
Primary completion :
12/31/2023
Completion :
12/31/2023
IDH1 • IDH2 • MGMT
|
IDH1 mutation
|
temozolomide
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/09/2021
Initiation :
03/30/2018
Primary completion :
07/31/2022
Completion :
07/31/2022
IDH1 • IDH2
|
IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132G • IDH1 R132V • IDH2 R140Q • IDH2 R172 • IDH2 R172G
|
Lynparza (olaparib)
Phase 1
Sabine Mueller, MD, PhD
Recruiting
Last update posted :
09/03/2021
Initiation :
10/02/2020
Primary completion :
03/01/2022
Completion :
03/01/2025
PD-L1
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase N/A
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/03/2021
Initiation :
06/22/2004
VEGFA
Phase 2
The Affiliated Nanjing Drum Tower Hospital of N...
Recruiting
Last update posted :
09/03/2021
Initiation :
09/01/2021
Primary completion :
05/01/2023
Completion :
11/01/2023
MGMT
|
Focus V (anlotinib) • penpulimab (AK105)
Phase 1/2
Virginia Commonwealth University
Recruiting
Last update posted :
09/02/2021
Initiation :
05/01/2019
Primary completion :
01/31/2022
Completion :
01/31/2024
EGFR
|
EGFR mutation
|
Nerlynx (neratinib) • sodium valproate
Phase N/A
xCures
Available
Last update posted :
09/02/2021
BRAF • NRAS • HRAS
|
BRAF mutation • ER mutation • HRAS mutation
|
ulixertinib (BVD-523)
Phase 2
Northwell Health
Recruiting
Last update posted :
08/31/2021
Initiation :
05/01/2016
Primary completion :
05/01/2024
Completion :
05/01/2025
EGFR
|
EGFR overexpression
|
Erbitux (cetuximab)
Phase 1b
Haukeland University Hospital
Recruiting
Last update posted :
08/27/2021
Initiation :
08/30/2018
Primary completion :
12/31/2022
Completion :
08/30/2023
MGMT
|
temozolomide • bortezomib
Phase 1
Huashan Hospital
Active, not recruiting
Last update posted :
08/25/2021
Initiation :
01/01/2017
Primary completion :
01/01/2020
Completion :
12/01/2021
PD-1
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
08/25/2021
Initiation :
07/06/2021
Primary completion :
06/01/2025
Completion :
06/01/2025
EGFR • MGMT • TERT
|
EGFR amplification • TERT promoter mutation • TERT mutation
|
Tecentriq (atezolizumab) • Actemra IV (tocilizumab)
Phase 1
St. Jude Children's Research Hospital
Recruiting
Last update posted :
08/25/2021
Initiation :
03/05/2018
Primary completion :
02/01/2025
Completion :
03/01/2025
PTCH1
|
PTCH1 mutation
|
Mekinist (trametinib) • gemcitabine • Kisqali (ribociclib) • Odomzo (sonidegib) • Neupogen (filgrastim)
Phase 2
Mayo Clinic
Recruiting
Last update posted :
08/25/2021
Initiation :
09/15/2017
Primary completion :
07/31/2022
Completion :
07/31/2022
PD-L1
|
Keytruda (pembrolizumab) • temozolomide
Phase 1
SCRI Development Innovations, LLC
Active, not recruiting
Last update posted :
08/23/2021
Initiation :
09/22/2015
Primary completion :
07/31/2021
Completion :
03/01/2022
MET
|
Avastin (bevacizumab) • Tabrecta (capmatinib)
Phase 1
National Institute of Neurological Disorders an...
Active, not recruiting
Last update posted :
08/23/2021
Initiation :
09/24/2018
Primary completion :
01/01/2022
Completion :
06/30/2022
IFNG
|
IFNG-H
|
Opdivo (nivolumab) • relatlimab (BMS-986016)
Phase 2
AHS Cancer Control Alberta
Not yet recruiting
Last update posted :
08/20/2021
Initiation :
12/01/2021
Primary completion :
01/01/2031
Completion :
01/01/2031
MGMT
|
MGMT promoter methylation
|
temozolomide
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
08/20/2021
Initiation :
11/12/2018
Primary completion :
11/01/2022
Completion :
11/01/2022
MGMT
|
Opdivo (nivolumab) • Avastin (bevacizumab)
Phase 2
The University of Hong Kong
Recruiting
Last update posted :
08/20/2021
Initiation :
01/01/2021
Primary completion :
12/31/2022
Completion :
12/31/2023
BRCA1 • BRCA2 • PTEN • BAP1 • CDK12 • RAD51B • BRIP1 • CHEK2 • FANCA • RAD51C • RAD51D • CHEK1 • RAD50 • FANCF • WRN • FANCD2 • FANCC
|
PTEN mutation
|
carboplatin • Talzenna (talazoparib)
Phase 2/3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
08/19/2021
Initiation :
12/15/2014
Primary completion :
12/01/2021
Completion :
12/01/2021
MGMT
|
temozolomide • veliparib (ABT-888)
Phase 1
Mayo Clinic
Active, not recruiting
Last update posted :
08/18/2021
Initiation :
06/21/2015
Primary completion :
07/13/2018
Completion :
01/01/2025
ALB
|
Leukine (sargramostim) • Reolysin (pelareorep)
Phase 1
Michael Gunn
Not yet recruiting
Last update posted :
08/18/2021
Initiation :
09/01/2021
Primary completion :
12/01/2021
Completion :
12/01/2022
MGMT • IFNG • GZMB
|
temozolomide • adecatumumab (MT201)
Phase 2
Dana-Farber Cancer Institute
Suspended
Last update posted :
08/16/2021
Initiation :
12/01/2021
Primary completion :
12/01/2023
Completion :
12/01/2024
CDKN2A • RB1 • CDKN2B • CASP3
|
CDKN2A deletion
|
Keytruda (pembrolizumab) • Verzenio (abemaciclib)
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
08/13/2021
Initiation :
05/20/2014
Primary completion :
12/31/2020
BRAF
|
Avastin (bevacizumab) • sapanisertib (TAK-228) • Mvasi (bevacizumab biosimilar) • Zirabev (bevacizumab biosimilar) • Krabeva (bevacizumab biosimilar) • BP102 (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CT-P16 (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • HD204 (bevacizumab biosimilar) • HLX-04 (bevacizumab biosimilar) • MIL 60 (bevacizumab biosimilar)
Phase 1
City of Hope Medical Center
Recruiting
Last update posted :
08/12/2021
Initiation :
08/14/2018
Primary completion :
12/15/2023
Completion :
12/15/2023
HER-2
|
HER-2 expression
|
MB-103
Phase 1/2
Gilead Sciences
Completed
Last update posted :
08/12/2021
Initiation :
12/17/2012
Primary completion :
03/01/2019
Completion :
08/13/2020
HER-2
|
HER-2 negative
|
Trodelvy (sacituzumab govitecan-hziy)
Phase 1/2
Nerviano Medical Sciences
Not yet recruiting
Last update posted :
08/12/2021
Initiation :
09/30/2021
Primary completion :
12/31/2024
Completion :
05/30/2025
IDH1 • IDH2 • MGMT
|
MGMT promoter methylation
|
temozolomide • lomustine • NMS-P293
Phase 2
Patrick Y. Wen, MD
Active, not recruiting
Last update posted :
08/11/2021
Initiation :
02/09/2017
Primary completion :
12/01/2021
Completion :
12/01/2022
IDH1
|
IDH1 R132H
|
temozolomide • Nerlynx (neratinib) • Verzenio (abemaciclib) • CC-115
Phase 2
University of Florida
Active, not recruiting
Last update posted :
08/11/2021
Initiation :
02/23/2018
Primary completion :
02/01/2023
Completion :
02/01/2023
MGMT
|
Keytruda (pembrolizumab) • temozolomide
Phase 2b
Imvax
Not yet recruiting
Last update posted :
08/10/2021
Initiation :
10/01/2021
Primary completion :
06/01/2023
Completion :
08/01/2025
MGMT
|
temozolomide • IGV-001
Phase N/A
NaviFUS Corporation
Recruiting
Last update posted :
08/04/2021
Initiation :
07/21/2020
Primary completion :
12/01/2022
Completion :
12/01/2022
FUS
|
Avastin (bevacizumab) • temozolomide
Phase 1
Washington University School of Medicine
Recruiting
Last update posted :
08/03/2021
Initiation :
07/14/2020
Primary completion :
08/31/2022
Completion :
07/31/2023
IDH1 • IDH2 • MGMT • CD8
|
IDH2 mutation
|
rocakinogene sifuplasmid (INO-9012) • GNOS-PV01 • neoantigen DNA vaccine
Phase 1
Patrick Y. Wen, MD
Recruiting
Last update posted :
08/03/2021
Initiation :
02/01/2021
Primary completion :
12/31/2022
Completion :
12/31/2023
ALB
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase 1a
HiberCell, Inc.
Recruiting
Last update posted :
08/02/2021
Initiation :
06/08/2021
Primary completion :
03/01/2022
Completion :
04/01/2022
HER-2
|
EGFR positive
|
HC-5404-FU
Phase 1
AstraZeneca
Recruiting
Last update posted :
08/02/2021
Initiation :
04/02/2018
Primary completion :
12/14/2023
Completion :
12/14/2023
IDH1
|
IDH1 mutation
|
AZD1390
Phase 2
Dana-Farber Cancer Institute
Recruiting
Last update posted :
08/02/2021
Initiation :
02/09/2017
Primary completion :
06/01/2022
Completion :
06/01/2024
CDKN2A • RB1 • CDK4 • CDKN2B • CDK6
|
CDKN2A deletion • CDK4 amplification
|
Verzenio (abemaciclib)
Phase 1
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
07/30/2021
Initiation :
07/13/2018
Primary completion :
07/31/2022
Completion :
07/31/2022
BRAF
|
WP1066
Phase 2
Clinique Neuro-Outaouais
Active, not recruiting
Last update posted :
07/28/2021
Initiation :
03/10/2017
Primary completion :
08/09/2021
Completion :
08/09/2021
PD-L1
|
temozolomide • Bavencio (avelumab)
Phase 2
Gary Archer Ph.D.
Recruiting
Last update posted :
07/28/2021
Initiation :
08/26/2020
Primary completion :
03/01/2025
Completion :
03/01/2025
MGMT • IL2RA • CD4 • FOXP3
|
temozolomide • varlilumab (CDX 1127)
Phase 2
The University of Texas Health Science Center a...
Not yet recruiting
Last update posted :
07/27/2021
Initiation :
09/01/2021
Primary completion :
02/01/2024
Completion :
02/01/2025
MGMT
|
Trodelvy (sacituzumab govitecan-hziy)
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
07/26/2021
Initiation :
05/12/2014
Primary completion :
01/31/2020
CASP3 • RPS6
|
sapanisertib (TAK-228)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
07/26/2021
Initiation :
02/25/2016
Primary completion :
01/31/2022
GNAQ • GNA11
|
GNAQ mutation • GNA11 mutation
|
Mekinist (trametinib)
Phase 1/2
Actuate Therapeutics Inc.
Recruiting
Last update posted :
07/23/2021
Initiation :
01/04/2019
Primary completion :
11/01/2022
Completion :
11/01/2023
HER-2 • BCL2
|
carboplatin • gemcitabine • Abraxane (albumin-bound paclitaxel) • irinotecan • pegylated liposomal doxorubicin • lomustine • 9-ING-41
Phase 3
Sumitomo Dainippon Pharma Oncology, Inc
Recruiting
Last update posted :
07/23/2021
Initiation :
12/08/2017
Primary completion :
09/01/2022
Completion :
11/01/2023
MGMT • HLA-A
|
Avastin (bevacizumab) • adegramotide/nelatimotide (DSP-7888)
Phase 1/2
Washington University School of Medicine
Recruiting
Last update posted :
07/22/2021
Initiation :
06/15/2016
Primary completion :
12/15/2023
Completion :
12/15/2023
BRAF • NF1
|
BRAF mutation • NF1 mutation
|
temozolomide • disulfiram
Phase 1
Children's Oncology Group
Recruiting
Last update posted :
07/22/2021
Initiation :
10/05/2015
Primary completion :
03/31/2022
AFP
|
Xpovio (selinexor)
Phase 2
University of California, Irvine
Active, not recruiting
Last update posted :
07/21/2021
Initiation :
03/01/2014
Primary completion :
03/01/2023
Completion :
03/01/2023
IL6 • IL2RA • CSF2 • IL10 • CD4
|
Avastin (bevacizumab) • cyclophosphamide oral • Mvasi (bevacizumab biosimilar) • Zirabev (bevacizumab biosimilar) • Gliovac (ERC1671) • Leukine (sargramostim) • cyclophosphamide intravenous
Phase 1/2
Nuvation Bio Inc.
Recruiting
Last update posted :
07/20/2021
Initiation :
12/08/2020
Primary completion :
08/01/2023
Completion :
12/01/2023
HER-2
|
HER-2 negative
|
NUV-422
Phase 1
Beijing Tiantan Hospital
Not yet recruiting
Last update posted :
07/20/2021
Initiation :
08/01/2021
Primary completion :
08/01/2022
Completion :
08/01/2024
IDH1 • IDH2 • IFNG
|
temozolomide
Phase 2
University of Pennsylvania
Recruiting
Last update posted :
07/19/2021
Initiation :
12/30/2019
Primary completion :
12/01/2025
Completion :
12/01/2025
MGMT
|
Zejula (niraparib)
Phase 1
Double Bond Pharmaceutical AB
Not yet recruiting
Last update posted :
07/19/2021
Initiation :
09/01/2021
Primary completion :
03/01/2023
Completion :
05/01/2023
MGMT
|
Temodex (temozolomide gel)
Phase 1b/2a
Enterome
Recruiting
Last update posted :
07/19/2021
Initiation :
07/13/2020
Primary completion :
08/01/2023
Completion :
08/01/2023
IFNG
|
Opdivo (nivolumab) • Avastin (bevacizumab) • EO2401
Phase 2/3
Laminar Pharmaceuticals
Recruiting
Last update posted :
07/19/2021
Initiation :
12/01/2019
Primary completion :
04/30/2022
Completion :
10/30/2023
IDH1 • MGMT
|
MGMT promoter methylation
|
temozolomide • Minerval (2-hydroxyoleic acid)
Phase 1
Yale University
Recruiting
Last update posted :
07/16/2021
Initiation :
04/21/2021
Primary completion :
12/01/2022
Completion :
07/01/2023
CD8 • FOXP3
|
zimberelimab (AB122) • domvanalimab (AB154)
Phase N/A
Hospices Civils de Lyon
Recruiting
Last update posted :
07/16/2021
Initiation :
12/04/2018
Primary completion :
01/04/2028
Completion :
01/04/2028
MUC16
|
BRAF V600E • EGFR mutation • BRAF V600 • ALK fusion • ROS1 fusion • ALK-ROS1 fusion
|
cisplatin
Phase 1b
Istari Oncology, Inc.
Active, not recruiting
Last update posted :
07/13/2021
Initiation :
12/05/2017
Primary completion :
12/30/2021
Completion :
03/01/2022
NF1
|
NF1 mutation
|
PVS-RIPO
Phase 2
Hopital Foch
Not yet recruiting
Last update posted :
07/12/2021
Initiation :
10/01/2021
Primary completion :
10/01/2025
Completion :
10/01/2025
FGFR3 • TACC3
|
FGFR3 fusion
|
temozolomide • metformin
Phase 2
Medical College of Wisconsin
Recruiting
Last update posted :
07/12/2021
Initiation :
06/03/2021
Primary completion :
06/01/2025
Completion :
06/01/2026
MGMT
|
temozolomide
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
07/09/2021
Initiation :
03/13/2014
Primary completion :
12/31/2021
Completion :
12/31/2021
EGFR
|
EGFR amplification
|
lapatinib
Phase 2
Beijing Sanbo Brain Hospital
Recruiting
Last update posted :
07/07/2021
Initiation :
05/01/2021
Primary completion :
12/31/2023
Completion :
12/31/2024
IDH1 • IDH2
|
Avastin (bevacizumab) • AiRuiKa (camrelizumab)
Phase 1
Olivia Newton-John Cancer Research Institute
Active, not recruiting
Last update posted :
06/30/2021
Initiation :
12/05/2017
Primary completion :
01/25/2021
Completion :
09/22/2021
EPHA3
|
ifabotuzumab (KB004)
Phase 2
NRG Oncology
Recruiting
Last update posted :
06/28/2021
Initiation :
10/27/2014
Primary completion :
05/01/2024
Completion :
05/01/2026
CD4
|
temozolomide
Phase 2
European Organisation for Research and Treatmen...
Not yet recruiting
Last update posted :
06/25/2021
Initiation :
12/01/2021
Primary completion :
05/01/2024
Completion :
12/01/2024
IDH1 • MGMT
|
IDH1 R132H • MGMT promoter methylation
|
lomustine • Nplate (romiplostim)
Phase 1
Crimson Biopharm Inc.
Not yet recruiting
Last update posted :
06/21/2021
Initiation :
08/01/2021
Primary completion :
07/01/2023
Completion :
07/01/2024
EGFR
|
EGFR mutation • EGFR amplification
|
CM93
Phase 1
University of Virginia
Active, not recruiting
Last update posted :
06/18/2021
Initiation :
03/01/2018
Primary completion :
08/31/2021
Completion :
08/31/2022
EGFR • MGMT • IFNG
|
temozolomide
Phase 1
M.D. Anderson Cancer Center
Recruiting
Last update posted :
06/17/2021
Initiation :
02/19/2013
Primary completion :
02/28/2022
Completion :
02/28/2022
KIT
|
KIT mutation • KIT positive
|
imatinib • Yervoy (ipilimumab)
Phase 2
NYU Langone Health
Completed
Last update posted :
06/17/2021
Initiation :
03/17/2017
Primary completion :
08/29/2019
Completion :
08/29/2019
TMB • MSI • IDH1 • IDH2 • POLE • MLH1 • MSH6 • POLD1
|
TMB-H • IDH2 mutation
|
Bavencio (avelumab)
Phase 1/2
Institute of Cancer Research, United Kingdom
Recruiting
Last update posted :
06/17/2021
Initiation :
08/13/2018
Primary completion :
07/01/2022
Completion :
11/01/2022
PIK3CA • PTEN • AKT2
|
PIK3CA mutation • AKT1 mutation
|
Tecentriq (atezolizumab) • ipatasertib (GDC-0068)
Phase 1/2
Fred Hutchinson Cancer Research Center
Completed
Last update posted :
06/16/2021
Initiation :
02/25/2009
Primary completion :
07/06/2018
Completion :
01/20/2021
MGMT
|
MGMT promoter methylation
|
temozolomide • carmustine • Mozobil (plerixafor) • Neupogen (filgrastim) • TevaGrastim (filgrastim biosimilar) • peripheral blood stem cell transplantation
Phase 1
City of Hope Medical Center
Recruiting
Last update posted :
06/15/2021
Initiation :
02/26/2020
Primary completion :
02/06/2023
Completion :
02/06/2023
MMP2
|
MMP2-H
|
CLTX-CAR T cell therapy
Phase 1
City of Hope Medical Center
Suspended
Last update posted :
06/15/2021
Initiation :
03/07/2016
Primary completion :
12/31/2021
Completion :
12/31/2021
UGT1A1
|
irinotecan
Phase 1
University of Chicago
Recruiting
Last update posted :
06/15/2021
Initiation :
10/03/2018
Primary completion :
02/01/2022
Completion :
03/01/2022
BCL3
|
temozolomide • acetazolamide
Phase 2
Kintara Therapeutics, Inc.
Active, not recruiting
Last update posted :
06/08/2021
Initiation :
01/20/2017
Primary completion :
09/01/2021
Completion :
12/01/2021
MGMT
|
Avastin (bevacizumab) • temozolomide • dianhydrogalactitol (VAL-083)
Phase 2
NYU Langone Health
Recruiting
Last update posted :
06/08/2021
Initiation :
02/07/2018
Primary completion :
06/01/2021
Completion :
01/01/2022
MGMT
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase 2
Kintara Therapeutics, Inc.
Active, not recruiting
Last update posted :
06/08/2021
Initiation :
12/17/2017
Primary completion :
06/01/2021
Completion :
08/01/2021
MGMT
|
dianhydrogalactitol (VAL-083)
Phase 1/2
WPD Pharmaceuticals Sp. z o.o.
Not yet recruiting
Last update posted :
06/07/2021
Initiation :
07/15/2021
Primary completion :
01/31/2024
Completion :
01/31/2025
MGMT
|
berubicin (RTA 744)
Phase 1
M.D. Anderson Cancer Center
Recruiting
Last update posted :
05/31/2021
Initiation :
09/20/2020
Primary completion :
10/30/2023
Completion :
10/30/2023
MGMT
|
temozolomide • peposertib (M3814)
Phase 1b/2
Gan and Lee Pharmaceuticals, USA
Recruiting
Last update posted :
05/27/2021
Initiation :
07/15/2020
Primary completion :
09/01/2022
Completion :
09/01/2022
EGFR • BRAF • ALK • NTRK1 • ROS1 • NTRK
|
GLR2007
Phase N/A
Massive Bio, Inc.
Recruiting
Last update posted :
05/25/2021
Initiation :
01/01/2018
Primary completion :
06/01/2022
Completion :
12/01/2022
EGFR • HER-2 • BRAF • PD-L1 • KRAS • ALK • ER • TP53 • ABL1 • FLT3 • TMB • NRAS • BRCA1 • BRCA2 • PTEN • FGFR2 • NTRK1 • NTRK3 • ROS1 • BCL2 • IDH1 • NTRK2 • IDH2 • HRAS • NPM1 • STK11 • DNMT3A • PDGFRA • RB1 • JAK2 • ERBB3 • NF1 • AKT1 • POLE • CCND1 • MCL1 • PDGFRB • KDR • PBRM1 • PTCH1 • BCL6 • PD-1 • BAP1 • VEGFA • MAP2K2 • MDM2 • MSH6 • CDK4 • FBXW7 • MSH2 • ATRX • CTNNB1 • FGFR4 • TSC2 • WT1 • ERBB4 • TSC1 • CLDN18 • JAK1 • PD-L2 • RAF1 • MDM4 • POLD1 • CHEK2 • FANCA • CEBPA • JAK3 • RICTOR • AURKA • MSH3 • TGFBR2 • CDK6 • CHEK1 • GATA6 • AKT2 • BRCA • CCND3 • MAP3K1 • MYCL • CCND2 • CSF1R • GNAS • HDAC1 • PARP1 • PRDM1 • ZNF217 • CDKN1A • ERCC4 • GATA3 • PARP2 • SDHA
|
FGFR2 fusion • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation
Phase 2/3
AbbVie
Active, not recruiting
Last update posted :
05/24/2021
Initiation :
12/07/2015
Primary completion :
12/31/2021
Completion :
12/31/2021
EGFR • MGMT
|
EGFR mutation • EGFR amplification • EGFRvIII mutation
|
temozolomide • depatuxizumab mafodotin (ABT-414)
Phase 1
Dana-Farber Cancer Institute
Recruiting
Last update posted :
05/21/2021
Initiation :
11/01/2014
Primary completion :
01/01/2025
Completion :
01/01/2026
MGMT • IFNG
|
MGMT promoter methylation
|
Keytruda (pembrolizumab) • temozolomide • Neo Vax (NEO-PV-01)
Phase 1
University Hospital Tuebingen
Recruiting
Last update posted :
05/18/2021
Initiation :
05/03/2021
Primary completion :
05/02/2023
Completion :
05/02/2024
IDH1 • MGMT • HLA-A
|
temozolomide
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/17/2021
Initiation :
09/03/2013
Primary completion :
10/31/2021
ALB
|
adavosertib (AZD1775)
Phase 1b
Jonsson Comprehensive Cancer Center
Withdrawn
Last update posted :
05/12/2021
Initiation :
05/01/2021
Primary completion :
07/01/2025
Completion :
07/01/2026
SOX2 • NANOG
|
ONC201
Phase 1
AbbVie
Completed
Last update posted :
05/06/2021
Initiation :
10/10/2017
Primary completion :
04/14/2021
Completion :
04/14/2021
EGFR
|
EGFR overexpression
|
serclutamab talirine (ABBV-321)
Phase 
Maastricht Radiation Oncology
Active, not recruiting
Last update posted :
04/30/2021
Initiation :
04/10/2021
Primary completion :
09/01/2021
Completion :
01/01/2022
MGMT
|
MGMT promoter methylation
Phase 2
Chimerix
Withdrawn
Last update posted :
04/30/2021
Initiation :
02/15/2021
Primary completion :
12/31/2022
Completion :
06/30/2023
EGFR
|
EGFR amplification • EGFR expression • EGFRvIII expression
|
ONC201
Phase 3
Universitätsmedizin Mannheim
Recruiting
Last update posted :
04/30/2021
Initiation :
12/09/2016
Primary completion :
12/01/2023
Completion :
03/01/2024
MGMT
|
MGMT promoter methylation
|
temozolomide
Phase 1/2
Peter Siesjö
Completed
Last update posted :
04/28/2021
Initiation :
09/01/2019
Primary completion :
03/31/2021
Completion :
03/31/2021
IL6 • CCL2
Phase 1
M.D. Anderson Cancer Center
Recruiting
Last update posted :
04/28/2021
Initiation :
02/12/2019
Primary completion :
05/31/2022
Completion :
05/31/2022
IDH1
|
tasadenoturev (DNX-2401)
Phase N/A
Istari Oncology, Inc.
Available
Last update posted :
04/21/2021
ALB
|
PVS-RIPO
Phase 2/3
VU University Medical Center
Recruiting
Last update posted :
04/19/2021
Initiation :
08/31/2018
Primary completion :
01/01/2022
Completion :
01/01/2022
MGMT
|
MGMT promoter methylation
|
Sutent (sunitinib) • lomustine
Phase 4
Novartis Pharmaceuticals
Recruiting
Last update posted :
04/19/2021
Initiation :
11/04/2019
Primary completion :
05/29/2026
Completion :
05/29/2026
NF1
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
Phase 1
Stanton Gerson MD
Active, not recruiting
Last update posted :
04/19/2021
Initiation :
11/22/2011
Primary completion :
12/07/2020
Completion :
11/01/2021
CD34
|
temozolomide • peripheral blood stem cell transplantation
Phase N/A
Fondazione I.R.C.C.S. Istituto Neurologico Carl...
Not yet recruiting
Last update posted :
04/15/2021
Initiation :
05/01/2021
Primary completion :
05/01/2021
Completion :
12/01/2022
FUS
Phase 2/3
Oslo University Hospital
Recruiting
Last update posted :
04/14/2021
Initiation :
04/26/2018
Primary completion :
05/01/2023
Completion :
05/01/2025
MGMT
|
temozolomide
Phase 1
St. Jude Children's Research Hospital
Active, not recruiting
Last update posted :
04/13/2021
Initiation :
11/19/2018
Primary completion :
04/02/2021
Completion :
06/01/2024
ALB
|
paxalisib (GDC-0084)
Phase 1
Providence Health & Services
Active, not recruiting
Last update posted :
04/13/2021
Initiation :
12/02/2019
Primary completion :
11/01/2023
Completion :
11/01/2025
MGMT
|
temozolomide
Phase N/A
Neuromed IRCCS
Recruiting
Last update posted :
04/12/2021
Initiation :
06/26/2019
Primary completion :
06/26/2019
Completion :
12/30/2021
IDH1 • MGMT • ATRX • GFAP
|
MGMT promoter methylation
Phase 2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
03/30/2021
Initiation :
12/01/2009
Primary completion :
11/01/2021
Completion :
11/01/2021
EGFR
|
Erbitux (cetuximab) • irinotecan
Phase 1b/2
Forma Therapeutics, Inc.
Active, not recruiting
Last update posted :
03/29/2021
Initiation :
11/01/2018
Primary completion :
09/01/2021
Completion :
04/01/2022
IDH1
|
Opdivo (nivolumab) • cisplatin • gemcitabine • azacitidine • olutasidenib (FT-2102)
Phase 2
University of California, San Francisco
Completed
Last update posted :
03/24/2021
Initiation :
06/29/2009
Primary completion :
06/03/2014
Completion :
06/03/2014
PD-L1 • PTPRC • ITGAM
|
PD-L1 expression
|
temozolomide • Oncophage (Heat Shock Protein Peptide Complex-96)
Phase 1
St. Joseph's Hospital and Medical Center, Phoenix
Recruiting
Last update posted :
03/22/2021
Initiation :
12/21/2018
Primary completion :
06/30/2021
Completion :
07/31/2022
PIK3CA • PTEN • CDKN2A • mTOR • CCND1 • CDK4 • CDKN2B • PIK3R1 • PIK3CB • PIK3C2B
|
PIK3CA mutation • CCND1 amplification • CDK4 amplification • MTOR mutation • PIK3CA mutation + PTEN mutation • PIK3R1 mutation
|
everolimus • Kisqali (ribociclib)
Phase 2/3
Sahlgrenska University Hospital, Sweden
Completed
Last update posted :
03/18/2021
Initiation :
01/01/2017
Primary completion :
01/15/2021
Completion :
01/15/2021
CRP
|
temozolomide • lomustine • disulfiram
Phase 2
Oblato, Inc.
Recruiting
Last update posted :
03/17/2021
Initiation :
06/12/2020
Primary completion :
05/25/2022
Completion :
10/25/2022
MGMT
|
temozolomide • disufenton sodium (OKN-007)
Phase 1
Vanderbilt-Ingram Cancer Center
Active, not recruiting
Last update posted :
03/15/2021
Initiation :
07/01/2013
Primary completion :
06/01/2015
Completion :
01/01/2022
IDH1
|
Avastin (bevacizumab) • temozolomide • l-methylfolate
Phase 2
photonamic GmbH & Co. KG
Not yet recruiting
Last update posted :
03/10/2021
Initiation :
04/01/2021
Primary completion :
11/01/2022
Completion :
11/01/2026
MGMT • CD4
|
MGMT promoter methylation
Phase 1
Gary Archer Ph.D.
Completed
Last update posted :
03/09/2021
Initiation :
04/24/2007
Primary completion :
07/06/2016
Completion :
07/06/2016
IL2RA • IL7R • NCAM1 • CD4
|
NCAM1 expression
|
temozolomide • ITI-1020 • Simulect (basiliximab)
Phase 1
Vigeo Therapeutics, Inc.
Active, not recruiting
Last update posted :
03/09/2021
Initiation :
11/28/2017
Primary completion :
12/01/2021
Completion :
03/01/2022
CD36 • BRCA
|
BRCA mutation
|
VT1021
Phase 1
University of Pennsylvania
Completed
Last update posted :
03/03/2021
Initiation :
03/11/2019
Primary completion :
02/27/2021
Completion :
02/27/2021
EGFR • MGMT • TERT
|
EGFR amplification • MGMT promoter methylation • TERT promoter mutation • EGFRvIII expression • TERT mutation
|
Keytruda (pembrolizumab) • CART-EGFRvIII T cells
Phase 1
Sidney Kimmel Comprehensive Cancer Center at Jo...
Completed
Last update posted :
02/17/2021
Initiation :
10/18/2017
Primary completion :
08/19/2020
Completion :
08/19/2020
CD4
|
TILs
|
temozolomide
Phase 1/2
Emory University
Recruiting
Last update posted :
02/17/2021
Initiation :
01/15/2021
Primary completion :
08/15/2023
Completion :
08/15/2023
EGFR
|
EGFR mutation
|
Visudyne (verteporfin)
Phase 1
University of Pennsylvania
Recruiting
Last update posted :
02/12/2021
Initiation :
02/20/2020
Primary completion :
12/02/2021
Completion :
12/02/2022
HRD
|
HRD • PARP1 expression
Phase 1
Santosh Kesari
Active, not recruiting
Last update posted :
02/12/2021
Initiation :
12/01/2016
Primary completion :
12/01/2021
Completion :
12/01/2022
EGFR
|
EGFR mutation • EGFR amplification
|
Gilotrif (afatinib)
Phase 1
City of Hope Medical Center
Recruiting
Last update posted :
02/11/2021
Initiation :
05/18/2015
Primary completion :
01/18/2022
Completion :
01/18/2022
IL13RA2
Phase 1/2
Genenta Science
Recruiting
Last update posted :
02/10/2021
Initiation :
03/05/2019
Primary completion :
12/01/2022
Completion :
12/01/2022
MGMT
|
Temferon (Autologous CD34+ enriched HSPCs expressing interferon-alpha 2)
Phase 2
Wake Forest University Health Sciences
Recruiting
Last update posted :
02/05/2021
Initiation :
01/27/2021
Primary completion :
08/01/2022
Completion :
01/30/2023
MGMT
|
Sunosi (solriamfetol)
Phase 2
University of Pennsylvania
Recruiting
Last update posted :
02/05/2021
Initiation :
06/23/2020
Primary completion :
06/01/2025
Completion :
06/01/2025
MGMT • TERT
|
EGFR amplification • TERT promoter mutation • TERT mutation
|
retifanlimab (INCMGA0012) • ragifilimab (INCAGN1876)
Phase 1/2
Shenzhen BinDeBio Ltd.
Recruiting
Last update posted :
02/04/2021
Initiation :
09/01/2019
Primary completion :
05/01/2021
Completion :
12/01/2021
MSLN • CTAG1B • HLA-A
|
HLA-A*02:01 positive • MSLN positive • HLA-A positive
|
multi-target gene-modified CAR-T/TCR-T cell immunotherapy
Phase 3
Bristol-Myers Squibb
Active, not recruiting
Last update posted :
02/03/2021
Initiation :
03/01/2016
Primary completion :
01/17/2019
Completion :
08/31/2021
TMB • MGMT
|
Opdivo (nivolumab) • temozolomide
Phase N/A
Xinhua Hospital, Shanghai Jiao Tong University ...
Active, not recruiting
Last update posted :
02/01/2021
Initiation :
10/27/2018
Primary completion :
01/31/2021
Completion :
03/01/2021
NF1
Phase 2
Second Affiliated Hospital, School of Medicine,...
Recruiting
Last update posted :
01/26/2021
Initiation :
01/15/2021
Primary completion :
12/01/2022
Completion :
12/01/2023
MGMT
|
temozolomide • Focus V (anlotinib)
Phase 1
M.D. Anderson Cancer Center
Recruiting
Last update posted :
01/15/2021
Initiation :
08/13/2018
Primary completion :
10/31/2021
Completion :
10/31/2021
MGMT
|
tinostamustine (EDO-S101)
Phase 2b
Grupo Español de Investigación en Neurooncología
Completed
Last update posted :
01/12/2021
Initiation :
08/22/2014
Primary completion :
06/01/2019
Completion :
06/14/2019
MGMT • MSH6
|
temozolomide
Phase 1/2
Celgene
Recruiting
Last update posted :
01/08/2021
Initiation :
01/02/2020
Primary completion :
03/29/2021
Completion :
08/24/2021
ALB
|
trotabresib (CC-90010)
Phase 1
Andrew B Lassman, MD
Completed
Last update posted :
01/07/2021
Initiation :
01/07/2011
Primary completion :
11/22/2016
Completion :
12/31/2018
EGFR
|
EGFR mutation • EGFRvIII mutation
|
erlotinib
Phase 1
Nader Sanai
Recruiting
Last update posted :
12/31/2020
Initiation :
07/21/2020
Primary completion :
12/31/2022
Completion :
07/29/2023
TACC3 • CASP3
|
FGFR3 mutation • FGFR3 K650E
|
Truseltiq (infigratinib)
Phase 1
Nader Sanai
Recruiting
Last update posted :
12/31/2020
Initiation :
07/08/2020
Primary completion :
12/01/2021
Completion :
02/01/2022
CDKN2A • CDK4 • CDKN2B • CASP3
|
CDK4 amplification
|
Verzenio (abemaciclib) • temuterkib (LY3214996)
Phase 1
Novartis Pharmaceuticals
Completed
Last update posted :
12/18/2020
Initiation :
07/01/2012
Primary completion :
04/01/2015
Completion :
04/01/2015
HER-2 • PGR
|
HR positive
|
buparlisib (BKM120) • Odomzo (sonidegib)
Phase 1
Edward Pan
Recruiting
Last update posted :
12/15/2020
Initiation :
12/13/2019
Primary completion :
10/24/2021
Completion :
10/24/2022
CDKN2A • RB1 • CDK4 • CDKN2B
|
CDK4 amplification
|
Avastin (bevacizumab) • Verzenio (abemaciclib)
Phase 2
University of Zurich
Recruiting
Last update posted :
12/15/2020
Initiation :
10/21/2020
Primary completion :
12/01/2022
Completion :
12/01/2023
PD-L1 • PD-1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • temozolomide
Phase 1
St. Joseph's Hospital and Medical Center, Phoenix
Completed
Last update posted :
12/11/2020
Initiation :
02/17/2016
Primary completion :
11/29/2018
Completion :
07/12/2019
CASP3
|
Zykadia (ceritinib)
Phase 1/2
University Hospital, Geneva
Recruiting
Last update posted :
12/11/2020
Initiation :
10/25/2018
Primary completion :
10/30/2021
Completion :
11/10/2023
PD-L1
|
HLA-A*02:01 positive
|
Keytruda (pembrolizumab) • Hiltonol (poly-ICLC) • IMA950
Phase 1
St. Joseph's Hospital and Medical Center, Phoenix
Completed
Last update posted :
12/10/2020
Initiation :
07/01/2014
Primary completion :
12/31/2015
Completion :
03/25/2019
CDK1
|
adavosertib (AZD1775)
Phase 1
City of Hope Medical Center
Recruiting
Last update posted :
12/09/2020
Initiation :
09/26/2019
Primary completion :
12/01/2022
Completion :
12/01/2022
PD-L1 • IFNG • CD123
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase 2
Jonsson Comprehensive Cancer Center
Active, not recruiting
Last update posted :
12/09/2020
Initiation :
11/28/2018
Primary completion :
11/01/2021
Completion :
11/01/2022
EGFR • TP53
|
TP53 mutation • EGFR mutation • EGFR amplification
|
Tagrisso (osimertinib)
Phase 1
University Hospital, Basel, Switzerland
Completed
Last update posted :
12/08/2020
Initiation :
11/16/2018
Primary completion :
11/01/2020
Completion :
11/01/2020
EGFR
|
EGFR amplification
|
Erbitux (cetuximab)
Phase 1
Gary Archer Ph.D.
Active, not recruiting
Last update posted :
11/26/2020
Initiation :
12/07/2016
Primary completion :
02/01/2021
Completion :
09/01/2021
IFNG
|
temozolomide
Phase 2
Immunomic Therapeutics, Inc.
Recruiting
Last update posted :
11/23/2020
Initiation :
08/01/2016
Primary completion :
06/01/2023
Completion :
06/01/2024
IL2
|
temozolomide • ITI-1020
Phase 2
Virginia Commonwealth University
Active, not recruiting
Last update posted :
11/13/2020
Initiation :
04/11/2013
Primary completion :
08/27/2020
Completion :
06/30/2022
PDGFRA
|
Nexavar (sorafenib) • sildenafil
Phase N/A
Institut Claudius Regaud
Recruiting
Last update posted :
11/06/2020
Initiation :
01/17/2020
Primary completion :
09/01/2029
Completion :
09/01/2029
PD-1 • CD4
|
CD8 expression
Phase 1/2
National Cancer Institute (NCI)
Completed
Last update posted :
10/30/2020
Initiation :
03/01/2002
Primary completion :
06/01/2005
EGFR
|
gefitinib
Phase N/A
VU University Medical Center
Not yet recruiting
Last update posted :
10/19/2020
Initiation :
01/01/2021
Primary completion :
11/01/2023
Completion :
11/01/2024
IL2RA
|
dexamethasone
Phase 2
Istituto Oncologico Veneto IRCCS
Active, not recruiting
Last update posted :
10/15/2020
Initiation :
11/01/2015
Primary completion :
07/01/2017
Completion :
10/01/2021
MGMT
|
Stivarga (regorafenib) • lomustine
Phase 1
Array Biopharma, now a wholly owned subsidiary ...
Completed
Last update posted :
10/14/2020
Initiation :
01/01/2006
Primary completion :
06/01/2009
Completion :
06/01/2009
HER-2
|
varlitinib (ASLAN001)
Phase N/A
Centre Leon Berard
Recruiting
Last update posted :
10/13/2020
Initiation :
01/16/2019
Primary completion :
08/16/2021
Completion :
08/16/2021
FOLH1
|
FOLH1 expression
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Completed
Last update posted :
10/13/2020
Initiation :
09/14/2017
Primary completion :
08/31/2019
Completion :
06/05/2020
MGMT
|
PT2385
Phase 1/2
Northwestern University
Recruiting
Last update posted :
10/12/2020
Initiation :
10/01/2020
Primary completion :
08/01/2024
Completion :
09/01/2025
IDH1
|
IDH1 R132H
|
Abraxane (albumin-bound paclitaxel)
Phase 2
Ever Supreme Bio Technology Co., Ltd.
Recruiting
Last update posted :
10/05/2020
Initiation :
06/06/2019
Primary completion :
12/31/2021
Completion :
06/30/2022
PD-L1 • IDH1 • CD8 • PD-1
|
PD-1-L
|
ADCV01
Phase 1
Johann Wolfgang Goethe University Hospital
Recruiting
Last update posted :
09/25/2020
Initiation :
12/01/2017
Primary completion :
09/01/2022
Completion :
12/01/2022
HER-2
|
HER-2 positive
|
HER2.tank
Phase 2
Kyrre Eeg Emblem
Recruiting
Last update posted :
09/23/2020
Initiation :
10/01/2019
Primary completion :
10/01/2023
Completion :
12/31/2023
MGMT
|
temozolomide • losartan potassium
Phase 2
Jonsson Comprehensive Cancer Center
Completed
Last update posted :
09/21/2020
Initiation :
06/01/2006
Primary completion :
10/01/2013
Completion :
08/01/2015
MGMT
|
MGMT promoter methylation
|
Avastin (bevacizumab) • temozolomide
Phase 1/2
Wuerzburg University Hospital
Recruiting
Last update posted :
09/17/2020
Initiation :
02/07/2018
Primary completion :
04/30/2024
Completion :
04/30/2024
IFNG • IL2RA • CD4
|
Opdivo (nivolumab) • cyclophosphamide intravenous
Phase 2
Shandong Cancer Hospital and Institute
Not yet recruiting
Last update posted :
09/17/2020
Initiation :
09/01/2020
Primary completion :
08/01/2021
Completion :
08/01/2022
ALB
|
temozolomide
Phase 1
The Cooper Health System
Not yet recruiting
Last update posted :
09/17/2020
Initiation :
11/01/2020
Primary completion :
12/31/2022
Completion :
12/31/2025
ALB
Phase 1b/2a
Esperas Pharma Inc.
Recruiting
Last update posted :
09/16/2020
Initiation :
05/01/2016
Primary completion :
03/27/2020
Completion :
06/01/2021
HER-2 • ER • PGR
|
HER-2 negative • ER expression
|
gemcitabine • ESP-01
Phase 3
Bristol-Myers Squibb
Active, not recruiting
Last update posted :
09/11/2020
Initiation :
05/05/2016
Primary completion :
02/11/2022
Completion :
08/01/2023
MGMT
|
Opdivo (nivolumab) • temozolomide
Phase 1/2
Northwell Health
Recruiting
Last update posted :
09/10/2020
Initiation :
06/01/2016
Primary completion :
06/01/2022
Completion :
06/01/2022
EGFR
|
EGFR overexpression
|
Erbitux (cetuximab)
Phase 2
Huashan Hospital
Recruiting
Last update posted :
09/09/2020
Initiation :
03/01/2012
Primary completion :
11/01/2020
Completion :
02/01/2021
IDH1 • IDH2 • TERT
|
TERT mutation
Phase 1/2
AbbVie
Completed
Last update posted :
09/03/2020
Initiation :
08/24/2015
Primary completion :
08/27/2020
Completion :
08/27/2020
EGFR
|
EGFR amplification
|
temozolomide • depatuxizumab mafodotin (ABT-414)
Phase 1/2
Heinrich Elinzano, MD
Completed
Last update posted :
08/26/2020
Initiation :
11/30/2017
Primary completion :
04/10/2020
Completion :
04/10/2020
ALB
|
temozolomide • Onivyde (nanoliposomal irinotecan)
Phase 2
Annick Desjardins
Completed
Last update posted :
08/05/2020
Initiation :
02/01/2016
Primary completion :
07/10/2019
Completion :
04/27/2020
EGFR
|
EGFR amplification
|
futuximab/modotuximab (Sym004)
Phase 1
Basilea Pharmaceutica
Recruiting
Last update posted :
07/31/2020
Initiation :
06/07/2017
Primary completion :
06/15/2021
Completion :
06/15/2022
MGMT
|
lisavanbulin (BAL101553)
Phase 1/2
Centre Hospitalier Universitaire de Besancon
Recruiting
Last update posted :
07/31/2020
Initiation :
05/26/2020
Primary completion :
07/01/2021
Completion :
07/01/2023
IFNG
|
temozolomide • UCPVax
Phase N/A
Sheba Medical Center
Recruiting
Last update posted :
07/28/2020
Initiation :
07/30/2020
Primary completion :
07/30/2022
Completion :
12/30/2022
IL6 • TNFA
|
temozolomide
Phase 2
Jonsson Comprehensive Cancer Center
Withdrawn
Last update posted :
07/24/2020
Initiation :
12/01/2019
Primary completion :
12/01/2020
Completion :
12/01/2022
PD-L1 • MGMT
|
MGMT promoter methylation
|
Opdivo (nivolumab) • DCVax-L (autologous dendritic cell vaccine leaded with autologous tumor cell lysate)
Phase 1
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Recruiting
Last update posted :
07/22/2020
Initiation :
01/25/2019
Primary completion :
07/31/2021
Completion :
07/31/2021
GLI1
|
GLI1 overexpression
|
ZSP1602
Phase 2
Arog Pharmaceuticals, Inc.
Completed
Last update posted :
07/20/2020
Initiation :
04/01/2016
Primary completion :
07/01/2020
Completion :
07/01/2020
PDGFRA
|
crenolanib besylate (ARO-002)
Phase N/A
Centre Hospitalier Universitaire, Amiens
Completed
Last update posted :
07/16/2020
Initiation :
04/30/2018
Primary completion :
11/08/2019
Completion :
11/08/2019
PTPRC
|
PTPRC expression
Phase 2
Samsung Medical Center
Recruiting
Last update posted :
07/15/2020
Initiation :
04/30/2018
Primary completion :
12/31/2020
Completion :
07/31/2021
EGFR
|
EGFR amplification
|
GC-1118A
Phase N/A
University Hospital Tuebingen
Active, not recruiting
Last update posted :
07/13/2020
Initiation :
06/01/2015
Primary completion :
06/01/2020
Completion :
06/01/2021
IDH1
Phase 1
Northwestern University
Recruiting
Last update posted :
07/02/2020
Initiation :
08/13/2019
Primary completion :
06/09/2022
Completion :
06/01/2023
MGMT
|
Opdivo (nivolumab) • temozolomide • linrodostat (BMS-986205)
Phase 1
Hutchison Medipharma Limited
Recruiting
Last update posted :
06/16/2020
Initiation :
01/26/2018
Primary completion :
06/30/2020
Completion :
08/31/2020
EGFR
|
EGFR amplification
|
epitinib (HMPL-813)
Phase 1/2
Sumitomo Dainippon Pharma Co., Ltd.
Completed
Last update posted :
06/09/2020
Initiation :
04/01/2016
Primary completion :
01/01/2020
Completion :
01/01/2020
PD-L1 • WT1
|
PD-L1 expression
|
adegramotide/nelatimotide (DSP-7888)
Phase 2
Heinrich-Heine University, Duesseldorf
Recruiting
Last update posted :
05/27/2020
Initiation :
03/06/2018
Primary completion :
09/06/2022
Completion :
06/06/2023
MGMT
|
MGMT promoter methylation
|
temozolomide
Phase 2
AbbVie
Completed
Last update posted :
05/25/2020
Initiation :
02/17/2015
Primary completion :
06/24/2019
Completion :
06/24/2019
EGFR
|
EGFR mutation • EGFR amplification • EGFRvIII mutation
|
temozolomide • lomustine • depatuxizumab mafodotin (ABT-414)
Phase 1/2
Second Affiliated Hospital, School of Medicine,...
Recruiting
Last update posted :
05/19/2020
Initiation :
05/01/2022
Primary completion :
06/01/2024
Completion :
07/01/2024
CD276
|
temozolomide • BP102
Phase 1
Second Affiliated Hospital, School of Medicine,...
Recruiting
Last update posted :
05/12/2020
Initiation :
06/01/2020
Primary completion :
05/01/2022
Completion :
07/01/2022
CD276
|
temozolomide • BP102 • BP102 (bevacizumab biosimilar)
Phase 1
Xijing Hospital
Recruiting
Last update posted :
05/07/2020
Initiation :
05/30/2019
Primary completion :
10/30/2020
Completion :
05/30/2022
BSG
|
CD147-CART
Phase 1/2
University Hospital Heidelberg
Recruiting
Last update posted :
02/27/2020
Initiation :
05/07/2018
Primary completion :
09/30/2023
Completion :
09/30/2024
BRAF
|
Tecentriq (atezolizumab) • Ibrance (palbociclib) • Alecensa (alectinib) • Torisel (temsirolimus) • Erivedge (vismodegib) • idasanutlin (RO5503781) • APG 101.10 • Apocept (asunercept)
Phase 
Assiut University
Not yet recruiting
Last update posted :
02/25/2020
Initiation :
03/01/2020
Primary completion :
07/01/2020
Completion :
09/01/2022
PD-L1
|
PD-L1 expression
Phase 2
Marco G Paggi, MD, PhD
Recruiting
Last update posted :
01/13/2020
Initiation :
12/15/2019
Primary completion :
06/15/2022
Completion :
12/15/2022
IDH2 • MGMT
|
temozolomide • chlorpromazine
Phase 2
NYU Langone Health
Withdrawn
Last update posted :
01/13/2020
Initiation :
11/01/2016
Primary completion :
06/01/2019
Completion :
06/01/2019
CD8 • CD4
|
Avastin (bevacizumab) • Hiltonol (poly-ICLC)
Phase 2
Novartis Pharmaceuticals
Completed
Last update posted :
12/04/2019
Initiation :
12/09/2013
Primary completion :
10/03/2018
Completion :
10/03/2018
FGFR2 • FGFR3 • FGFR1 • TACC3 • TACC1
|
FGFR2 mutation • FGFR2 fusion • FGFR3-TACC3 fusion • FGFR1 mutation • FGFR3 fusion • FGFR1 fusion
|
Truseltiq (infigratinib)
Phase 1
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
11/22/2019
Initiation :
07/08/2011
Primary completion :
11/15/2019
Completion :
11/15/2019
MGMT
|
MGMT promoter methylation
|
Avastin (bevacizumab)
Phase 1
Center Trials & Treatment Europe
Not yet recruiting
Last update posted :
09/17/2019
Initiation :
12/10/2019
Primary completion :
09/15/2020
Completion :
11/15/2020
IDH2 • MGMT
|
IDH2 mutation • MGMT promoter methylation
|
temozolomide
Phase 1
Engeneic Pty Limited
Recruiting
Last update posted :
08/29/2019
Initiation :
10/25/2016
Primary completion :
12/01/2019
Completion :
06/01/2020
EGFR
|
Vectibix (panitumumab) • doxorubicin hydrochloride • EGFR EDV • doxorubicin encapsulated nanocells (EGFREDVDox)
Phase 1/2
National Cancer Institute (NCI)
Completed
Last update posted :
08/21/2019
Initiation :
05/16/2012
Primary completion :
11/01/2018
Completion :
01/17/2019
EGFR
|
EGFR expression
|
fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous
Phase 1/2
Centre Jean Perrin
Completed
Last update posted :
08/14/2019
Initiation :
06/08/2015
Primary completion :
08/01/2019
Completion :
08/01/2019
PTEN • IDH1
|
temozolomide • ralimetinib (LY 2228820)
Phase 1/2
National Cancer Institute (NCI)
Completed
Last update posted :
08/13/2019
Initiation :
02/01/2012
Primary completion :
03/28/2018
Completion :
03/28/2018
ALB
|
temozolomide • veliparib (ABT-888)
Phase 2
Children's Oncology Group
Completed
Last update posted :
08/07/2019
Initiation :
07/01/2005
Primary completion :
09/01/2012
Completion :
06/30/2017
ALB
|
temozolomide • lomustine
Phase 1
Boston Biomedical, Inc
Completed
Last update posted :
08/01/2019
Initiation :
11/01/2015
Primary completion :
08/01/2018
Completion :
09/01/2018
MUC16 • HLA-A
|
adegramotide/nelatimotide (DSP-7888)
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
07/24/2019
Initiation :
01/24/2007
Primary completion :
03/09/2011
Completion :
09/04/2018
KIT • SRC
|
dasatinib
Phase 1
Sunovion
Completed
Last update posted :
07/17/2019
Initiation :
07/31/2012
Primary completion :
05/17/2017
Completion :
05/17/2017
WT1
|
WT2725
Phase N/A
AbbVie
No Longer Available
Last update posted :
07/15/2019
EGFR
|
EGFR mutation • EGFR amplification • EGFRvIII mutation
|
depatuxizumab mafodotin (ABT-414)
Phase 2
Radiation Therapy Oncology Group
Active, not recruiting
Last update posted :
05/07/2019
Initiation :
01/01/2005
Primary completion :
02/01/2013
MGMT
|
temozolomide
Phase 1
Baylor College of Medicine
Completed
Last update posted :
04/25/2019
Initiation :
10/01/2010
Primary completion :
06/01/2014
Completion :
03/07/2018
HER-2
|
HER-2 positive • HER-2 expression
|
AU-105
Phase 2
Eli Lilly and Company
Completed
Last update posted :
04/05/2019
Initiation :
10/01/2007
Primary completion :
02/01/2010
Completion :
03/01/2016
GSK3B
|
Kinenza (enzastaurin)
Phase 1/2
Patrick Y. Wen, MD
Completed
Last update posted :
03/05/2019
Initiation :
05/25/2007
Primary completion :
08/31/2013
Completion :
10/10/2017
ALB
|
temozolomide • Caprelsa (vandetanib)
Phase 1
Leaf Vertical Inc.
Not yet recruiting
Last update posted :
02/26/2019
Initiation :
06/01/2019
Primary completion :
09/30/2019
Completion :
12/31/2020
MGMT
|
MGMT promoter methylation
|
temozolomide • cannabidiol (BRCX014)
Phase 2
Patrick Y. Wen, MD
Active, not recruiting
Last update posted :
02/25/2019
Initiation :
09/01/2011
Primary completion :
10/01/2016
Completion :
02/01/2019
PIK3CA • PTEN • PIK3R1
|
PIK3CA mutation • PTEN mutation • PTEN deletion • PIK3R1 mutation
|
buparlisib (BKM120)
Phase 1
Boehringer Ingelheim
Completed
Last update posted :
02/18/2019
Initiation :
09/17/2009
Primary completion :
09/12/2017
Completion :
09/12/2017
MGMT
|
Gilotrif (afatinib) • temozolomide
Phase 2
Dartmouth-Hitchcock Medical Center
Completed
Last update posted :
10/10/2018
Initiation :
05/01/2006
Primary completion :
04/01/2008
Completion :
07/01/2013
CD4
|
temozolomide
Phase N/A
Institut Claudius Regaud
Completed
Last update posted :
08/27/2018
Initiation :
05/01/2013
Primary completion :
04/01/2018
Completion :
04/01/2018
CD133 • SOX2
|
CD133 expression
Phase 1
Providence Health & Services
Completed
Last update posted :
08/17/2018
Initiation :
01/08/2014
Primary completion :
06/18/2018
Completion :
08/15/2018
CTAG1B
|
amoxicillin • trimethoprim/sulfamethoxazole
Phase 2
Massachusetts General Hospital
Completed
Last update posted :
08/16/2018
Initiation :
04/01/2010
Primary completion :
09/01/2015
Completion :
09/01/2015
EGFR
|
EGFR amplification
|
Vizimpro (dacomitinib)
Phase 
Huashan Hospital
Not yet recruiting
Last update posted :
08/15/2018
Initiation :
08/10/2018
Primary completion :
08/10/2019
Completion :
05/01/2020
IDH1
|
temozolomide
Phase 1
immatics Biotechnologies GmbH
Completed
Last update posted :
08/07/2018
Initiation :
10/01/2014
Primary completion :
06/01/2018
Completion :
06/01/2018
HLA-A • CSF2
|
temozolomide • APVAC1 vaccine • Hiltonol (poly-ICLC) • Leukine (sargramostim)
Phase 
Central Hospital, Nancy, France
Recruiting
Last update posted :
08/03/2018
Initiation :
10/01/2012
Primary completion :
10/01/2015
Completion :
10/01/2020
BCL2 • CCND1 • VEGFA • HIF1A • CASP3 • ATF6 • ERN1 • SIRT1
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
08/01/2018
Initiation :
06/01/2008
Primary completion :
10/01/2010
Completion :
07/01/2011
ABCB1 • ABCG2
|
Cilcane (cilengitide)
Phase 1/2
National Cancer Institute (NCI)
Completed
Last update posted :
07/31/2018
Initiation :
07/12/2011
Primary completion :
06/30/2015
Completion :
01/31/2017
VEGFA • CXCL12 • FGF
|
Avastin (bevacizumab) • Zolinza (vorinostat)
Phase N/A
Assistance Publique Hopitaux De Marseille
Recruiting
Last update posted :
07/24/2018
Initiation :
07/02/2018
Primary completion :
01/01/2022
Completion :
05/01/2022
MMP2 • MMP9
|
temozolomide
Phase 1/2
GlaxoSmithKline
Completed
Last update posted :
07/24/2018
Initiation :
11/10/2011
Primary completion :
11/12/2015
Completion :
02/25/2016
HER-2 • PGR • PTEN
|
HER-2 negative
|
GSK2636771
Phase 1b
DNAtrix, Inc.
Completed
Last update posted :
07/16/2018
Initiation :
09/11/2014
Primary completion :
03/15/2018
Completion :
03/15/2018
IFNG
|
tasadenoturev (DNX-2401) • Actimmune (interferon gamma-1 b)
Phase 1/2
National Cancer Institute (NCI)
Completed
Last update posted :
07/02/2018
Initiation :
04/01/2006
Primary completion :
02/01/2010
Completion :
09/01/2012
EGFR
|
erlotinib • Nexavar (sorafenib) • Torisel (temsirolimus) • Zarnestra (tipifarnib)
Phase 1
University of Virginia
Active, not recruiting
Last update posted :
06/07/2018
Initiation :
03/01/2016
Primary completion :
09/01/2019
Completion :
01/01/2020
RB1 • CDK4 • CDK6
|
Kisqali (ribociclib)
Phase 2
Hoffmann-La Roche
Completed
Last update posted :
04/30/2018
Initiation :
08/19/2013
Primary completion :
01/13/2017
Completion :
05/05/2017
PD-1
|
Avastin (bevacizumab) • temozolomide • lomustine
Phase 1
City of Hope Medical Center
Completed
Last update posted :
04/17/2018
Initiation :
12/01/2010
Primary completion :
03/01/2013
Completion :
03/01/2013
LYN
|
bafetinib (INNO-406)
Phase 3
Sun Yat-sen University
Recruiting
Last update posted :
02/23/2018
Initiation :
04/01/2015
Primary completion :
04/01/2020
Completion :
05/01/2023
IFNA1
Phase 1/2
Frank Lieberman
Completed
Last update posted :
02/07/2018
Initiation :
12/01/2006
Primary completion :
09/01/2009
Completion :
06/01/2016
ALK
|
HLA-A2 positive
Phase N/A
University of Nebraska
Completed
Last update posted :
01/31/2018
Initiation :
09/01/2011
Primary completion :
09/01/2017
Completion :
09/01/2017
MMP2 • MMP9
Phase N/A
Center Trials & Treatment
No Longer Available
Last update posted :
01/10/2018
EGFR • TMB
|
Keytruda (pembrolizumab) • temozolomide
Phase 2
Biotech Pharmaceutical Co., Ltd.
Completed
Last update posted :
01/03/2018
Initiation :
08/18/2010
Primary completion :
03/23/2017
Completion :
03/23/2017
EGFR • MGMT
|
EGFR expression • EGFR positive
|
temozolomide • TheraCIM (nimotuzumab)
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
11/28/2017
Initiation :
08/01/2006
Primary completion :
10/01/2015
Completion :
10/01/2015
KDR • EPAS1 • CA9
|
VEGFA overexpression • CA9 expression • VEGFA expression
|
Avastin (bevacizumab) • irinotecan
Phase 1
AbbVie
Completed
Last update posted :
11/21/2017
Initiation :
04/02/2013
Primary completion :
06/19/2017
Completion :
06/19/2017
EGFR
|
EGFR amplification • EGFR expression
|
temozolomide • depatuxizumab mafodotin (ABT-414)
Phase 1
AbbVie (prior sponsor, Abbott)
Completed
Last update posted :
11/21/2017
Initiation :
11/01/2010
Primary completion :
11/01/2012
Completion :
11/01/2012
EGFR
|
EGFR mutation • EGFR expression • EGFR overexpression
|
depatuxizumab (ABT-806)
Phase 1/2
Assistance Publique - Hôpitaux de Paris
Recruiting
Last update posted :
11/06/2017
Initiation :
10/12/2017
Primary completion :
05/01/2019
Completion :
09/01/2021
CD4
|
TG6002
Phase N/A
University of Pisa
Completed
Last update posted :
10/25/2017
Initiation :
03/01/2015
Primary completion :
12/01/2016
Completion :
03/01/2017
BCL2
|
temozolomide
Phase 1/2
TVAX Biomedical
Completed
Last update posted :
10/12/2017
Initiation :
04/01/2010
Primary completion :
03/01/2011
Completion :
03/01/2011
CSF2
|
TVI-Brain-1
Phase N/A
CANbridge Life Sciences Ltd.
Not yet recruiting
Last update posted :
09/21/2017
Initiation :
11/01/2017
Primary completion :
12/01/2017
Completion :
12/31/2017
FAS
|
Apocept (asunercept)
Phase 2
Radiation Therapy Oncology Group
Not yet recruiting
Last update posted :
09/11/2017
Initiation :
11/01/2014
Primary completion :
05/01/2019
CD4
|
temozolomide
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
08/16/2017
Initiation :
02/01/2010
Primary completion :
05/01/2012
Completion :
06/01/2012
CD133
|
Erivedge (vismodegib)
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
08/11/2017
Initiation :
01/01/2008
Primary completion :
06/01/2012
Completion :
06/01/2012
BCL2
|
R-(-)-gossypol (AT 101)
Phase 1
Pediatric Brain Tumor Consortium
Completed
Last update posted :
08/07/2017
Initiation :
08/01/2013
Primary completion :
04/01/2015
Completion :
04/01/2015
ALB
|
TP53 mutation
Phase N/A
University Medicine Greifswald
Completed
Last update posted :
08/01/2017
Initiation :
01/01/2016
Primary completion :
10/01/2016
Completion :
12/01/2016
CD40
|
CD40 expression
Phase 2
Clinica Universidad de Navarra, Universidad de ...
Completed
Last update posted :
04/11/2017
Initiation :
06/01/2015
Primary completion :
03/01/2017
Completion :
03/01/2017
PD-L1
|
PD-L1 expression
|
Opdivo (nivolumab)